Vancouver, British Columbia--(Newsfile Corp. - April 2, 2014) - OxySure Systems (OTCQB: OXYS) announced that its OxySure Model 615 portable emergency oxygen device has received CE Mark approval, a critical step toward launching this unique product into the 30 countries belonging to the European Economic Area. OxySure is a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology.

InvestmentPitch.com has produced a "video news alert" discusses the recent activities of OxySure. If this link is not enabled, please visit www.InvestmentPitch.com and enter "OxySure" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_80sqvnh9/OxySure-Systems-OTCQB-OXYS-Model-615-Portable-Emergency-Oxygen-Device-Receives-CE-Mark-Approval-for-Sale-in-Europe

An estimated 90 million Europeans currently suffer from life threatening respiratory diseases, with approximately 250,000 dying each year from asthma and other respiratory diseases.

Julian T. Ross, CEO stated, "We are excited to introduce our innovative, lifesaving product to the European market. Our product can now bear the CE Mark, which demonstrates that the OxySure Model 615 complies with stringent requirements related to the quality, safety, and performance of medical oxygen devices found in the applicable European Union laws."

First responders typically provide supplemental oxygen to patients immediately upon arrival. OxySure's Model 615 allows lay rescuers to begin oxygen delivery sooner, bridging the gap until professional responders arrive on the scene. It releases medically pure oxygen when two inert powders within its single use cartridge are combined, thereby eliminating the need for storage cylinders or tanks. Users simply plug in the mask, turn the knob, and place the mask over the nose and mouth. Early administration of medical oxygen in respiratory emergencies can often save a trip to the hospital.

Model 615, available over the counter and FDA approved requiring no prescription, has already been used in connection with thousands of saves in the US alone including cardiac arrest, asthma attacks, sickle cell disease issues, COPD exacerbations, allergy attacks, heat exhaustion, hypoxia/altitude sickness, migraine attacks, poisoning and diabetic emergencies. The OxySure Model 615 is sold through more than 40 distributors in the US and overseas distributors in Australia and New Zealand, the UK, Brazil, Chile, and Hong Kong. The Company plans to appoint new distributors in the coming months in European countries where the Company does not currently have representation.

The OxySure Model 615 is a perfect companion product to external automated defibrillators, of which there are 3 million units installed worldwide. In the long term, Model 615 promises to be like a fire extinguisher, of which there are more than 100 million units installed in the US alone.

New York-based Taglich Brothers has a speculative buy recommendation on the company, with a 12-mointh target price of $2.10.

Analyst Juan Noble stated, "We project a revenue ramp from $2 million in 2013 to $4.9 million in 2015. As the OxySure Model 615 gains traction, revenue should increase to $18 million by 2017. That long-term revenue estimate is based on moderate acceptance of the Model 615, mainly as a companion to automatic external defibrillators."

The company currently trades at $0.72, well below the $2.10 target price, and with 24.2 million shares outstanding, the company is capitalized at $17.4 million.

For more information about OxySure, please visit the company's website www.oxysure.com.

Investor relations is handled by Stonegate Securities, which can be reached at 214-987-4121 or by email at investors@oxysure.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases, research reports and other market information. Please visit InvestmentPitch.com and browse the extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com